au en false false Default
HLTHAU VanEck Global Healthcare Leaders ETF Please read important information Close important disclosure false

    • HLTH
    VanEck Global Healthcare Leaders ETF

    HLTH
    VanEck Global Healthcare Leaders ETF

    • NAV
      $12.12

      as at 21-Aug-26
    • Total Net Assets
      $57.04M
    • Dividend Frequency
      1 each year
    • Management fee (p.a.)
      0.45%
    • Number of securities
      50
    • Inception Date
      08-Sep-20
    HLTH

    Overview

    Fund description

    Our global healthcare ETF, HLTH gives investors exposure to a diversified portfolio of the largest international companies from the global healthcare sector. Our global healthcare ETF aims to provide investment returns, before fees and other costs, which track the performance of the Index. 

    Why consider HLTH?

    Global growth opportunity

    A sector with significant growth potential due to shifting global demographics, social changes, research & development and innovation supporting increased demand in healthcare-related products and services.

    A portfolio of global healthcare leaders comprising the most fundamentally strong companies

    Invests in 50 fundamentally sound and attractively valued companies with the best growth prospects in the healthcare sector.

    Targeted exposure and diversification

    A portfolio which targets focused exposure to healthcare and offers true diversification by equally weighting across companies.

    Who is TICKER suitable for?

      is likely to be appropriate for a consumer who is seeking capital preservation and a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 3 years, and has a medium risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 7 years, and has a very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a satellite allocation within a portfolio, has an investment timeframe of at least 7 years, and has an extremely high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a high to very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a major, core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital preservation and a regular income distribution, is intending to use the product as a core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 3 years, and has a medium risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 7 years, and has an extremely high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a high risk/return profile.
      is likely to be appropriate for a consumer who is seeking a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a minor or satellite allocation within a portfolio, has no investment timeframe, and has a high or very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking regular income distribution, is intending to use the product as a core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 3 years, and has a medium risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth, is intending to use the product as a satellite allocation within a portfolio, has no minimum investment timeframe, and has an extremely high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 3 years, and has a high risk/return profile.
      is likely to be appropriate for a consumer who is seeking a regular income distribution, is intending to use the product as a minor or satellite allocation within a portfolio, has an investment timeframe of at least 3 years, and has a medium risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital preservation and a regular income distribution, is intending to use the product as a standalone solution, major, core, minor or satellite allocation within a portfolio, has no investment timeframe and has a low risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a standalone solution or major, core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 3 years, and has a medium risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a standalone solution or major, core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a standalone solution or major, core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a high to very high risk/return profile.
      is likely to be appropriate for a consumer who is seeking capital growth and a regular income distribution, is intending to use the product as a core, minor or satellite allocation within a portfolio, has an investment timeframe of at least 5 years, and has a high risk/return profile.

    Performance

    Holdings & allocations

    All holdings (%) as at 21-Aug-26 Download all holdings

    No. of holdings: 50
    Holding name
    Ticker
    No. of securities held
    Market value
    % of Fund net
    assets
    Illumina Inc ILMN US 6,188 1,895,096 3.32
    Halozyme Therapeutics Inc HALO US 11,561 1,745,607 3.06
    Arrowhead Pharmaceuticals Inc ARWR US 13,369 1,625,591 2.85
    West Pharmaceutical Services Inc WST US 3,126 1,540,659 2.70
    Argenx Se ARGX US 1,051 1,525,417 2.67
    Dexcom Inc DXCM US 11,457 1,476,744 2.59
    Ypsomed Holding Ag YPSN SW 2,084 1,470,929 2.58
    Incyte Corp INCY US 7,953 1,418,862 2.49
    Merck & Co Inc MRK US 6,366 1,355,574 2.38
    Exelixis Inc EXEL US 17,846 1,347,169 2.36
    Eli Lilly & Co LLY US 747 1,309,022 2.29
    Teva Pharmaceutical Industries Ltd TEVA IT 24,910 1,282,752 2.25
    Novo Nordisk A/S NOVOB DC 19,451 1,275,473 2.24
    Alteogen Inc 196170 KS 3,953 1,273,736 2.23
    Tenet Healthcare Corp THC US 3,233 1,267,070 2.22
    Amgen Inc AMGN US 2,010 1,232,626 2.16
    Encompass Health Corp EHC US 7,333 1,231,481 2.16
    Neurocrine Biosciences Inc NBIX US 5,671 1,207,739 2.12
    Vertex Pharmaceuticals Inc VRTX US 1,568 1,199,529 2.10
    Orion Oyj ORNBV FH 9,260 1,195,741 2.10
    Fisher & Paykel Healthcare Corp Ltd FPH NZ 32,567 1,181,393 2.07
    Bristol-Myers Squibb Co BMY US 12,457 1,165,192 2.04
    Johnson & Johnson JNJ US 3,047 1,149,387 2.02
    Otsuka Holdings Co Ltd 4578 JP 10,700 1,145,799 2.01
    Kyowa Kirin Co Ltd 4151 JP 50,400 1,140,259 2.00
    Ipsen Sa IPN FP 4,223 1,124,346 1.97
    Alk-Abello A/S ALKB DC 22,949 1,080,431 1.89
    Samsung Biologics Co Ltd 207940 KS 690 1,077,615 1.89
    Globus Medical Inc GMED US 8,682 1,053,256 1.85
    Astellas Pharma Inc 4503 JP 49,700 1,041,722 1.83
    Daiichi Sankyo Co Ltd 4568 JP 41,700 1,037,533 1.82
    Resmed Inc RMD US 3,188 1,030,270 1.81
    Stryker Corp SYK US 2,185 1,004,813 1.76
    Gsk Plc GSK LN 27,373 998,732 1.75
    Idexx Laboratories Inc IDXX US 1,283 997,405 1.75
    Penumbra Inc PEN US 2,189 993,605 1.74
    United Therapeutics Corp UTHR US 1,373 983,408 1.72
    Sk Biopharmaceuticals Co Ltd 326030 KS 11,239 947,231 1.66
    Universal Health Services Inc UHS US 3,825 946,426 1.66
    Ucb Sa UCB BB 2,577 930,908 1.63
    Hoya Corp 7741 JP 4,239 926,656 1.62
    Astrazeneca Plc AZN SS 3,891 904,934 1.59
    Shionogi & Co Ltd 4507 JP 34,400 881,730 1.55
    Ensign Group Inc/The ENSG US 3,510 879,362 1.54
    Intuitive Surgical Inc ISRG US 1,559 824,350 1.45
    Alnylam Pharmaceuticals Inc ALNY US 2,348 774,211 1.36
    Chugai Pharmaceutical Co Ltd 4519 JP 12,510 770,159 1.35
    Boston Scientific Corp BSX US 10,646 748,519 1.31
    Insulet Corp PODD US 3,348 692,406 1.21
    Zoetis Inc ZTS US 6,366 690,716 1.21
    Other/Cash --   41,059 0.07
    Total 100.00
    These are not recommendations to buy or to sell any security.

    Dividends

    Election of Dividend Reinvestment Plan (DRP)

    You can elect DRP by logging into MUFG’s Investor Centre. Once you are logged in, please proceed to the “Payments and Tax” tab and select “Reinvestment Plans”.

    Documents & insights

    Research and resources

    Documents

    Market announcements

    HLTHAU https://google.com/
    Exchange Traded Funds (ETFs)
    Information about
    Education
    Connect with us